Novartis highlights advances for patients with breast cancer and hematological ... Reuters (press release) Everolimus - Results from a Phase II study evaluating everolimus as a monotherapy in relapsed/refractory Hodgkin lymphoma (ASH abstract #2717; December 11, 6:00 - 8:00PM) and data from a Phase I trial of everolimus in combination with rituximab or in ... |
